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Armando D’Angelo, MD,b Milan, ItalyHeparin-induced thrombocytopenia (HIT) is an immune-
mediated prothrombotic disorder that is often encountered
after cardiac surgery. The appropriate alternative anticoag-
ulant to be used in this setting is not univocal, especially
for the coexistence of renal failure and high bleeding risk.
Fondaparinux is a factor Xa inhibitor via the action of
antithrombin but devoid of antifactor II (thrombin) activity.
It is modeled after a critical heparin pentasaccharide se-
quence; although the drug is identical in structure to the
pentasaccharide domain found in heparin, it is too small
to be recognized by the majority of heparin-reactive anti-
bodies.1 We describe our early experience with fondapari-
nux in the management of HIT in critically ill patients after
cardiac surgery.CLINICAL SUMMARY
This retrospective cohort study was conducted on all
patients diagnosed with HIT at our tertiary care, university
cardiothoracic intensive care unit from January 2005 to De-
cember 2007. The diagnosis of HIT was based on clinico-
pathologic findings according to Warkentin and Greinacher.2
Fondaparinux was started after discontinuation of unfrac-
tionated or low-molecular-weight heparin; warfarin was
overlapped when the platelet count increased to more than
100 3 109/L. The dosage of fondaparinux was defined ac-
cording to creatinine clearance (CrCl) as calculated with
the Cockcroft-Gault formula: 7.5 mg/24 h for CrCl more
than 60 mL/min, 5 mg/24 h for CrCl between 30 and 60
mL/min, and 2.5 mg/24 h for CrCl less than 30 mL/min.RESULTS
During the study period, HIT was diagnosed in 18 patients
(1.4% of the overall cardiac surgical population); 11 pa-
tients received fondaparinux, and 8 patients received bivalir-From the Department of Cardiovascular Anesthesia and Intensive Care,a and Coagu-
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basis: The most critically ill patients (ventilated, on hemofil-
tration, recent surgery) were treated with bivalirudin. Patient
population data are presented in Tables 1 and 2.
The patients in the study group had a nadir platelet count
at the time of diagnosis between 8 and 723 109/L; the time
lag from surgery was 6 to 40 days. All patients had a prompt
increase of platelet count and decrease of HIT antibody titer.
The duration of treatment was 4 to 17 days.
During fondaparinux therapy, 3 episodes of major bleed-
ing (defined as life or organ threatening, requiring surgery
or> 3 units of packed red blood cells) were noted. Major
bleeding occurred in 3 patients with a CrCl less than 30
mL/min after low-risk procedures (epistaxis secondary to
placement of a nasojejunal tube, stomal bleeding after tra-
cheostomy, and hemothorax). They were treated by drug
discontinuation, transfusions. and surgical hemostasis.
One patient with a CrCl greater than 30 mL/min had supra-
therapeutic anti-Xa activity without any apparent bleeding.
No thromboembolic complications were recorded after ini-
tiation of therapy.DISCUSSION
Because patients with HIT are at increased risk for throm-
bosis, anticoagulation is warranted. Multiple options for
anticoagulation therapy are now available, placing an addi-
tional responsibility on health care workers for choosing
the optimal therapy for each patient. The synthetic pentasac-
charide fondaparinux binds to antithrombin and potentiates
its inhibition of factor Xa. Anecdotal evidence suggests
that fondaparinux may eventually prove to be valuable for
preventing and treating thrombosis in patients with HIT.
Furthermore, various small-scale in vitro studies have dem-
onstrated a lack of cross-reactivity between fondaparinux
and HIT antibodies.1 Multiple considerations need to be
addressed when choosing an anticoagulant in the patients
undergoing cardiac surgery.
The data reported suggest the following:
 On the basis of the theory of how coagulation factors in-
teract, the results of in vitro studies, and the clinical out-
comes, there is accumulating evidence that FXa may
represent a better target for inhibition than FIIa. This is
based on an understanding of the amplified nature of co-
agulation factor interactions and fibrin formation, the need
for smaller doses of an anticoagulant to block coagulationery c March 2010
TABLE 1. Patient characteristics
Patient Surgery Heparin treatment (d) Lowest platelet count HITAb OD SRA (%) Days from surgery
n 1 CABGþMV repairþRF 40 72,000 1.8 NA 40
n 2 AVR 5 52,000 2 NA 8
n 3 MVRþTV repairþRF 6 48,000 2 NA 8
n 4 AVRþascending aorta
replacement
6 11,000 1.5 NA 7
n 5 MVRþTVRþASD closure 10 61,000 0.68 NA 12
n 6 AVRþMVR 5 8000 NA 100 6
n 7 AVRþMVR 7 60,000 1.1 NA 7
n 8 MVRþTV repairþCABG 6 37,000 1.9 NA 6
n 9 MV repair 7 61,000 NA NA 11
n 10 TAAA 5 18,000 1.0 NA 7
n 11 CABG 5 13,000 1.5 NA 6
HIT Ab OD, Heparin-induced thrombocytopenia antibody optical density; SRA, serotonin release assay; NA, not available; MV, mitral valve; RF, radiofrequency; AVR, aortic valve
replacement; MVR, mitral valve replacement; TV, tricuspid valve; TVR, tricuspid valve replacement; ASD, atrial septal defect; CABG, coronary artery bypass grafting; TAAA, thor-
acoabdominal aortic aneurysm.
TABLE 2. Clinical results
Patient No. Creatinine clearance Duration of treatment (d) Bleeding Thrombosis Outcome
1 <30 mL/min CVVH 4 Epistaxis No Death
2 <30 mL/min 8 No No Death
3 55 mL/min 7 No No Discharged
4 <30 mL/min CVVH 4 Bleeding from tracheostomy No Death
5 >60 mL/min 7 No No Discharged
6 >30 mL/min 6 No Bilateral iliac and
femoral DVT
Discharged
7 45 mL/min 6 No No Discharged
8 <30 mL/min 7 No Popliteal artery Discharged
9 <30 mL/min CVVH 4 Hemothorax No Discharged
10 <30 mL/min 17 No Splanchnic vessels Discharged
11 <30 mL/min CVVH 6 No No Discharged
CVVH, Continuous venovenous hemofiltration; DVT, deep vein thrombosis.
Brief Research Reportsprogression earlier in the sequence of reactions, the evi-
dence for incomplete suppression of thrombin generation
with direct thrombin inhibitors, the evidence for rebound
hypercoagulability with thrombin inhibitors, and the clin-
ical results with fondaparinux.3
 Patients with renal failure have an increased risk of both
thrombotic and bleeding complications; however, sev-
eral antithrombotic drugs undergo renal clearance.
Therefore, estimation of renal function is necessary
when prescribing these drugs to patients with renal dys-
function.4
 Pharmacokinetic and clinical data in patients with chronic
renal impairment are limited for several anticoagulants,
and adequate administration information is often absent.
Lower doses and closer anticoagulation monitoring may
be advisable when these agents are used in patients with
chronic renal failure. We recommend that fondaparinux
sodium be used with caution in patients with moderate
or severe renal dysfunction and that guidelines for labora-The Journal of Thoracic and Catory monitoring and appropriate dose adjustments are ur-
gently required to ensure the safety of the patient. The
benefits of fondaparinux over enoxaparin when adminis-
tered for non–ST-segment elevation acute coronary syn-
drome are most marked among patients with renal
dysfunction and largely explained by lower rates of major
bleeding with fondaparinux.5CONCLUSIONS
On the basis of these observations in a small sample of
critically ill patients after cardiac surgery, we conclude
that fondaparinux provides an adjunctive tool in the arma-
mentarium for anticoagulation in postoperative patients
with HIT. Caution is advised in patients with poor renal
function, especially if foreseeing invasive procedures.
Anti-Xa activity monitoring is warranted in these patients,
and surgery should be delayed at least 36 hours after the
last administration of fondaparinux.rdiovascular Surgery c Volume 139, Number 3 791
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